Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

Véronique Dièras; Giuseppe Curigliano; Miguel Martin; Florence Lerebours; Junji Tsurutani; Marie-France Savard; Katarzyna J. Jerzak; Xichun Hu; Ciara C. O’Sullivan; Eriko Tokunaga; Alicia Okines; Chiun-Sheng Huang; William Jacot; Joohyuk Sohn; Eduardo Cronemberger Silva; Volkmar Mueller; Shan Yang; G. Granata; Qi Shen; Erika Hamilton; the HER2CLIMB-05 Investigators

doi:10.1007/s11523-026-01245-w

Enriched recordOpen access

Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

Véronique Dièras, Giuseppe Curigliano, Miguel Martin, Florence Lerebours, Junji Tsurutani, Marie-France Savard, Katarzyna J. Jerzak, Xichun Hu, Ciara C. O’Sullivan, Eriko Tokunaga, Alicia Okines, Chiun-Sheng Huang, William Jacot, Joohyuk Sohn, Eduardo Cronemberger Silva, Volkmar Mueller, Shan Yang, G. Granata, Qi Shen, Erika Hamilton, the HER2CLIMB-05 Investigators

Targeted Oncology2026doi:10.1007/s11523-026-01245-w

Citation graph

Abstract

No public abstract is available from the verified source records.

Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

Referenced works

Cited by

External reference records

External cited-by records